Share on StockTwits
 

Targacept (NASDAQ:TRGT) posted its quarterly earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.39) by $0.01, AnalystRatings.NET reports. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.59 million.

A number of research firms have recently commented on TRGT. Analysts at MKM Partners downgraded shares of Targacept from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 18th. They noted that the move was a valuation call. On a related note, analysts at Deutsche Bank cut their price target on shares of Targacept from $12.00 to $4.00 in a research note on Tuesday, December 17th.

Targacept (NASDAQ:TRGT) opened at 4.76 on Thursday. Targacept has a 52-week low of $3.75 and a 52-week high of $6.11. The stock’s 50-day moving average is $4.46 and its 200-day moving average is $4.96. The company’s market cap is $160.2 million.

Targacept, Inc is a biopharmaceutical company. The Company is engaged in the design, discovery and development of NNR Therapeutics for the treatment of diseases and disorders of the nervous system.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.